Comments

Monte Rosa Therapeutics Analyst Ratings

GLUENASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$18.06

1.619.79%

Last update: Dec 16, 1:26 PM

Overview News Earnings Options

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Overweight

Highest Price Target¹

$22.00

Lowest Price Target¹

$11.00

Consensus Price Target¹

$16.00

Monte Rosa Therapeutics Analyst Ratings and Price Targets | NASDAQ:GLUE | Benzinga

Monte Rosa Therapeutics Inc has a consensus price target of $16 based on the ratings of 6 analysts. The high is $22 issued by Wells Fargo on December 16, 2025. The low is $11 issued by JP Morgan on October 19, 2023. The 3 most-recent analyst ratings were released by Wells Fargo on December 16, 2025, November 7, 2025, and March 21, 2025, respectively. With an average price target of $15 between Wells Fargo, there's an implied -16.94% downside for Monte Rosa Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Wells Fargo

Wedbush

LifeSci Capital

Piper Sandler

JP Morgan

¹calculated from analyst ratings

Analyst Ratings for Monte Rosa Therapeutics

					Get Alert
Dec 16, 2025	21.82%	Derek ArchilaWells Fargo 71%	13 22	Previous Equal-Weight Current Overweight	Get Alert
Nov 7, 2025	-28.02%	Derek ArchilaWells Fargo 71%	10 13	Previous Equal-Weight Current Equal-Weight	Get Alert
Mar 21, 2025	-44.63%	Derek ArchilaWells Fargo 71%	10 11	Previous Equal-Weight Current Equal-Weight	Get Alert
Mar 21, 2025	-5.87%	Robert DriscollWedbush 53%	15 17	Previous Outperform Current Outperform	Get Alert
Mar 12, 2025	5.2%	—	19	Previous Initiates Current Outperform	Get Alert
Dec 19, 2024	-39.09%	Derek ArchilaWells Fargo 71%	11 14	Previous Overweight Current Equal-Weight	Get Alert
Sep 12, 2024	-39.09%	Robert DriscollWedbush 53%	11 11	Previous Outperform Current Outperform	Get Alert
Aug 12, 2024	-5.87%	Derek ArchilaWells Fargo 71%	17 18	Previous Overweight Current Overweight	Get Alert
Jun 28, 2024	-11.41%	Edward TenthoffPiper Sandler 57%	16 16	Previous Overweight Current Overweight	Get Alert
May 22, 2024	-39.09%	Robert DriscollWedbush 53%	11 11	Previous Outperform Current Outperform	Get Alert
Feb 15, 2024	-39.09%	Robert DriscollWedbush 53%	11	Previous Initiates Current Outperform	Get Alert
Oct 19, 2023	-39.09%	Eric JosephJP Morgan 47%	11 31	Previous Overweight Current Overweight	Get Alert
Aug 11, 2023	-39.09%	Richard LawCredit Suisse 63%	11	Previous Neutral Current Neutral	Get Alert
May 12, 2023	-39.09%	Richard LawCredit Suisse 63%	11	Previous Neutral Current Neutral	Get Alert
Mar 17, 2023	-39.09%	Richard LawCredit Suisse 63%	11 12	Previous Current Neutral	Get Alert
Jan 3, 2023	5.2%	Derek ArchilaWells Fargo 71%	19	Previous Equal-Weight Current Overweight	Get Alert

FAQ

What is the target price for Monte Rosa Therapeutics (GLUE) stock?

The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Wells Fargo on December 16, 2025. The analyst firm set a price target for $22.00 expecting GLUE to rise to within 12 months (a possible 21.82% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics upgraded their overweight rating.

When was the last upgrade for Monte Rosa Therapeutics (GLUE)?

The last upgrade for Monte Rosa Therapeutics Inc happened on December 16, 2025 when Wells Fargo raised their price target to $22. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.

When was the last downgrade for Monte Rosa Therapeutics (GLUE)?

The last downgrade for Monte Rosa Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from $14 to $11 for Monte Rosa Therapeutics Inc.

When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on December 16, 2025 so you should expect the next rating to be made available sometime around December 16, 2026.

Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a upgraded with a price target of $13.00 to $22.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $18.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.